Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A
Molecules · 2023
DOI: 10.3390/molecules28062815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Ying Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan. Hauptthemen laut MEDLINE: Myxococcales, Depsipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
The hard-to-culture slightly halophilic myxobacterium “Paraliomyxa miuraensis” SMH-27-4 produces antifungal cyclodepsipeptide miuraenamide A (1). Herein, the region (85.9 kbp) containing the biosynthetic gene cluster (BGC) coding the assembly of 1 was identified and heterologously expressed in Myxococcus xanthus. A biosynthetic pathway proposed using in silico analysis was verified through the gene disruption of the heterologous transformant. In addition to the core polyketide synthase (PKS) and nonribosomal peptide synthase (NRPS) genes, tyrosine halogenase and O-methyltransferase genes participated in the biosynthesis of 1 as their gene-disrupted mutants produced a new congener, debromomiuraenamide A (4), and a previously isolated congener, miuraenamide E (3), respectively. Multigene disruption provided a heterologous mutant that produced 1 with the highest yield among the prepared mutants. When fed on 3-bromo-L-tyrosine, this mutant produced more 1 in the yield of 1.21 mg/L, which was 20 times higher than that produced by the initially prepared heterologous transformant. Although this yield was comparable to that of the original producer SMH-27-4 (1 mg/L), the culture time was 4.5 times shorter than that of SMH-27-4, indicating a five-fold efficiency in productivity. The results indicate the great potential of the miuraenamide BGC for the future contribution to drug development through logical gene manipulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan.
ORCID-Profile: Makoto Ojika
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Liu, Y., Yamazaki, S., & Ojika, M. (2023). Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A. Molecules. https://doi.org/10.3390/molecules28062815
Vancouver
Liu Y, Yamazaki S, Ojika M. Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A. Molecules. 2023. doi:10.3390/molecules28062815
BibTeX
@article{Liu2023,
author = {Liu, Ying and Yamazaki, Satoshi and Ojika, Makoto},
title = {Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062815}
}
EUVIMED